Bristol-Myers Squibb Company (BMY)
| Market Cap | 93.57B |
| Revenue (ttm) | 47.70B |
| Net Income (ttm) | 5.05B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.49 |
| PE Ratio | 18.51 |
| Forward PE | 7.20 |
| Dividend | $2.48 (5.39%) |
| Ex-Dividend Date | Jul 3, 2025 |
| Volume | 714,256 |
| Open | 46.04 |
| Previous Close | 45.95 |
| Day's Range | 45.78 - 46.37 |
| 52-Week Range | 42.96 - 63.33 |
| Beta | 0.37 |
| Analysts | Hold |
| Price Target | 57.64 (+25.39%) |
| Earnings Date | Jul 31, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $57.64, which is an increase of 25.39% from the latest price.
News
3 SWANs On Sale
Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a li...
3 Dividend Stocks for August 2025
These three dividend payers have an average yield of 4.5%.
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity
Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focused ...
Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL).
Bristol-Myers Squibb: Buy The Weakness
Bristol-Myers Squibb faces political pressure on U.S. drug prices, but I see the risk as manageable given its strong fundamentals. The company's growth portfolio now exceeds half of revenue, offsettin...
Bristol-Myers Squibb: Declines Have Gone Too Far
Bristol-Myers Squibb's sales are stabilizing, with Q2 net sales up 1% YoY and growth portfolio drugs like Camzyos and Breyanzi showing strong momentum. Despite margin compression and profitability con...
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
BMY's double-beat FQ2'25 performance and raised FY2025 guidance have been met with much skepticism, as observed in the steep pullback post earnings. This is despite the Growth Portfolio comprising ove...
Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline
Bristol-Myers Squibb Company beat Q2 2025 revenue expectations and raised full-year guidance, but EPS guidance was lowered and shares remain under pressure. The company's growth portfolio is expanding...
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
Bristol-Myers Squibb's Q2 2025 results were a mixed bag, with revenues showing signs of recovery while earnings saw a pullback. A reduction in earnings guidance on IPRD charges was another disappointm...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat
Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization Officer Christopher S. B...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Bristol Myers posts better-than-expected second quarter results on strength of top sellers
Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most established and best-selling brands, blood thinner Eliquis and cancer treatments O...
Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Second Quarter Financial Results for 2025.
Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs
Nine of the top sixteen Barron's Better Bets 'Safer' dividend dogs are attractively priced, offering dividends from $1K invested exceeding their share price. Analyst projections suggest 18-29% net gai...
How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, examining historical stock performance around earnings announcements c...
Bristol Myers, Bain Capital form new company to develop immunology drugs
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the compan...
Bristol Myers Squibb and Bain Capital Form New Immunology Company
The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.